Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commissioner McClellan Visits Mass Bio: Phase IV, Orphan Drugs On Agenda

Executive Summary

Phase IV commitments should be discussed earlier in the review process to improve the cost-effectiveness of drug development, the Massachusetts Biotechnology Council told FDA Commissioner McClellan

You may also be interested in...



Phase IV Discussions Should Begin Earlier In Review Process, Wyeth Says

Wyeth wants FDA to direct reviewers to initiate Phase IV discussions with sponsors several weeks before a user fee action date

Phase IV Discussions Should Begin Earlier In Review Process, Wyeth Says

Wyeth wants FDA to direct reviewers to initiate Phase IV discussions with sponsors several weeks before a user fee action date

Genzyme Revises Fabrazyme Phase IV Proposal In Bid For April Approval

Genzyme's proposal for completing its Phase IV Fabrazyme study is the kind of innovative drug development proposal that FDA Commissioner McClellan is encouraging, Genzyme CEO Henri Termeer suggested during a March 5 conference call

Related Content

UsernamePublicRestriction

Register

PS041307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel